180 Life Sciences Corp. (ATNF)

USD 1.74

(-4.4%)

Market Cap (In USD)

3.43 Million

Revenue (In USD)

-

Net Income (In USD)

-19.93 Million

Avg. Volume

582.08 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.16-17.75
PE
-
EPS
-
Beta Value
0.247
ISIN
US68236V3024
CUSIP
68236V104
CIK
1690080
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Employee Count
-
Website
https://180lifesciences.com
Ipo Date
2017-06-27
Details
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.